Chennai: Pharma major Glenmark Pharmaceuticals Ltd on Tuesday announced Rufenamide tablets, 200 mg and 400 mg, the therapeutic equivalent of Banzel tablets, 200 mg and 400 mg Christian, Inc.
Glenmark said in a statement that it was one of the first brief New Drug Application (ANDA) applicants to submit a sufficiently complete ANDA for rufenamide tablets.
Commenting on the launch, Sanjeev Krishna, President, Glenmark North America, said: “We are delighted to be one of the first generic companies in the US to offer a low-cost alternative to Benzyl tablets, 200 mg and 400 mg. has been.”
According to IQVIA sales data for the 12-month period ended April 2021, the Banzel tablet, 200 mg and 400 mg market achieved annual sales of approximately $ 285.3 million.
Glenmark’s current portfolio includes 172 products authorized for distribution in US marketplaces and 45 pending ANDA approvals with the US Food and Drug Administration (USFDA).